Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ribomic, Inc. ( (JP:4591) ) has shared an update.
Ribomic Inc. reported its non-consolidated financial results for the three months ended June 30, 2025, showing no operating revenues and a net loss of 227 million yen, consistent with the previous year’s performance. The company’s financial position remains stable with a high equity ratio, but it continues to forecast a full-year loss, indicating ongoing financial challenges.
More about Ribomic, Inc.
Ribomic Inc. is a company listed on the Tokyo Stock Exchange, operating in the biotechnology sector. The company focuses on developing innovative therapeutic solutions, although specific products or services are not detailed in the release.
Average Trading Volume: 2,173,257
Technical Sentiment Signal: Buy
Current Market Cap: Yen5.31B
For an in-depth examination of 4591 stock, go to TipRanks’ Overview page.